Elizabeth Holmes — a single drop of blood that proved nothing

In San Jose, California, on January 3, 2022, a federal jury convicted Elizabeth Holmes, the founder and chief executive of the blood-testing company Theranos, of defrauding the investors who had made her, on paper, one of the wealthiest self-made women in the world. The company she built around a claim that a few drops of blood from a finger-prick could run a full battery of laboratory tests had raised hundreds of millions of dollars on a technology that did not work. The jury found that she had known, and had sold the promise anyway.

The verdict was partial but decisive. After a trial that began in San Jose in September 2021 and ran nearly four months, the jury found Holmes guilty on four of eleven counts: one count of conspiracy to defraud investors and three counts of wire fraud tied to specific investor transfers. It acquitted her on four counts related to defrauding patients and failed to reach a verdict on three further investor counts, on which the judge declared a mistrial and prosecutors declined to retry her. On November 18, 2022, U.S. District Judge Edward Davila sentenced her to 135 months, eleven years and three months, in federal prison, followed by three years of supervised release. He later ordered Holmes and her co-defendant to pay $452,047,268 in restitution to twelve defrauded investors.

Theranos, founded in 2003, had at its 2014 peak been valued at roughly $9 billion, with Holmes’s stake notionally worth about $5 billion. The company promised that its proprietary device, marketed under the name Edison, could perform hundreds of diagnostic tests on a sample of only a few drops of blood, displacing the needle and the laboratory tube. It never delivered. Theranos ran most patient tests on modified commercial analyzers made by other companies, and the finger-prick results it did produce were frequently unreliable.

What distinguished the Theranos fraud was not a falsified balance sheet but a falsified product. There was no Ponzi structure and no embezzled cash; there was a machine said to do something it could not do, sold to investors, to retail partners, and ultimately to patients whose medical decisions depended on the numbers it returned. The case became the defining parable of an era in which Silicon Valley’s tolerance for unproven promises collided with the unforgiving standards of clinical medicine.